← CATALYST PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($18.1m) | ($18.4m) | ($34.0m) | $31.9m | $75.0m | $39.5m | $83.1m | $71.4m | $163.9m | $214.3m | — | |
| Depreciation | $43k | $46k | $38k | $54k | $92k | $192k | $141k | $316k | $397k | $375k | $330k | |
| Amortization of Intangible Assets | — | — | — | — | — | $0 | $1.1m | $32.6m | $37.4m | $37.5m | — | |
| Amortization Cash Flow | — | — | — | — | — | — | $1.1m | $32.6m | $37.4m | $37.5m | — | |
| Amortization Of Intangibles | — | — | — | — | — | — | $1.1m | $32.6m | $37.4m | $37.5m | $37.9m | |
| Depreciation Amortization Depletion | — | — | — | — | — | — | $1.2m | $32.9m | $37.8m | $37.9m | $38.2m | |
| Deferred Income Tax Expense (Benefit) | — | — | — | $0 | ($33.0m) | $9.3m | — | — | — | ($6.8m) | ($6.9m) | |
| Deferred taxes | — | — | — | — | ($33.0m) | $9.3m | $4.9m | ($17.8m) | ($9.4m) | ($6.8m) | — | |
| Deferred Income Tax | — | — | — | — | — | — | $4.9m | ($17.8m) | ($9.4m) | ($6.8m) | ($6.9m) | |
| Share-based Payment Arrangement, Noncash Expense | $1.8m | $2.4m | $3.6m | $3.8m | $6.3m | $6.1m | $7.9m | $14.2m | $22.3m | $24.8m | $25.2m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $11k | — | $4k | $0 | $56k | $153k | $230k | $982k | $668k | $1.8m | — | |
| Stock-based compensation | $1.8m | $2.4m | $3.6m | $3.8m | $6.3m | $6.1m | $7.9m | $14.2m | $22.3m | $24.8m | $25.2m | |
| Payment of employee withholding tax related to stock-based compensation | ($11k) | — | ($4k) | $0 | ($56k) | ($153k) | ($230k) | ($982k) | ($668k) | ($1.8m) | — | |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | — | — | $0 | $0 | $0 | $0 | — | |
| Asset Impairment Charge | — | — | — | — | — | — | — | $0 | $0 | $464k | $464k | |
| Other Nonoperating Income (Expense) | $322k | $454k | $1.3m | $1.6m | $587k | $282k | $2.9m | $7.7m | $21.1m | $25.7m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Change In Working Capital | — | — | — | — | — | — | $13.7m | ($37.3m) | $30.9m | ($60.9m) | ($66.9m) | |
| Increase (Decrease) in Accounts Receivable | — | — | — | $10.5m | ($4.5m) | $632k | $3.8m | $43.1m | $12.0m | $61.0m | ($59.6m) | |
| Accounts receivable, net | — | — | — | ($10.5m) | $4.5m | ($632k) | ($3.8m) | ($43.1m) | ($12.0m) | ($61.0m) | ($59.6m) | |
| Change In Receivables | — | — | — | — | — | — | ($3.8m) | ($43.1m) | ($12.0m) | ($61.0m) | ($59.6m) | |
| Changes In Account Receivables | — | — | — | — | — | — | ($3.8m) | ($43.1m) | ($12.0m) | ($61.0m) | ($59.6m) | |
| Increase (Decrease) in Inventories | — | — | $56k | $1.9m | $2.7m | $3.2m | ($1.1m) | $4.7m | $3.9m | $18.1m | ($15.6m) | |
| Acquired research and development inventory expensed from asset acquisition | — | — | — | — | — | — | $4.1m | $0 | $0 | — | — | |
| Acquired inventory samples expensed from asset acquisition | — | — | — | — | — | — | $0 | $130k | $0 | $0 | — | |
| Inventory reserve and write-offs | — | — | — | — | — | — | — | $0 | $0 | $464k | — | |
| Inventory, net | — | — | ($56k) | ($1.9m) | ($2.7m) | ($3.2m) | $1.1m | ($4.7m) | ($3.9m) | ($18.1m) | ($15.6m) | |
| Change In Inventory | — | — | — | — | — | — | $1.1m | ($4.7m) | ($3.9m) | ($18.1m) | ($15.6m) | |
| Increase (Decrease) in Accounts Payable | ($861k) | $1.0m | $392k | $1.8m | $139k | ($1.5m) | $1.2m | $10.8m | $1.8m | ($5.4m) | ($4.0m) | |
| Change In Payables And Accrued Expense | — | — | — | — | — | — | $17.6m | $16.6m | $55.6m | $18.8m | ($4.0m) | |
| Accrued expenses and other liabilities | ($480k) | $1.1m | $4.9m | $12.5m | ($1.2m) | $5.5m | $16.4m | $5.8m | $53.8m | $24.2m | — | |
| Accrued milestone payment classified as license and acquired intangibles, net | — | — | — | — | — | — | — | $0 | $0 | $12.5m | — | |
| Change In Accrued Expense | — | — | — | — | — | — | $16.4m | $5.8m | $53.8m | $24.2m | $17.5m | |
| Prepaid expenses and other current assets | $457k | ($126k) | ($476k) | ($2.7m) | ($4.0m) | $4.0m | ($807k) | ($5.8m) | ($8.5m) | ($177k) | — | |
| Change In Other Current Liabilities | — | — | — | — | — | — | ($307k) | ($338k) | ($369k) | ($401k) | ($410k) | |
| Net Cash Provided by (Used in) Operating Activities | ($18.0m) |
($13.7m)
+23.50%
|
($25.7m)
-87.04%
|
$34.6m
+234.65%
|
$45.0m
+30.12%
|
$60.4m
+34.06%
|
$116.0m
+92.22%
|
$143.6m
+23.74%
|
$239.8m
+67.00%
|
$208.7m
-12.98%
|
$208.2m
-0.22%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $96k | — | $92k | $19k | $11k | $1.0m | $29k | $231k | $556k | $58k | ($373k) | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | — | $0 | $762k | $0 | $0 | $0 | — | |
| Payments to Acquire Investments | — | — | $36.8m | $34.7m | $10.0m | $10.0m | — | — | — | — | $0 | |
| Payments in connection with asset acquisitions | — | — | — | — | — | — | ($10.0m) | ($198.3m) | $0 | $0 | — | |
| Net Other Investing Changes | — | — | — | — | — | — | ($10.0m) | ($198.3m) | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | $3.6m | ($4k) | ($15.5m) | $37.2m | ($5.0m) | ($11.0m) | $9.2m | ($293.5m) | ($556k) | ($58k) | ($85k) | |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common Stock | — | — | — | — | — | $12.1m | $6.9m | $0 | $0 | $25.3m | — | |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | $0 | $141.0m | $0 | $0 | |
| Repurchase of common stock | — | — | — | — | — | ($12.1m) | ($6.9m) | $0 | $0 | ($25.3m) | — | |
| Payment of fees in connection with issuance of common stock | — | — | — | — | — | — | — | $0 | ($296k) | $0 | — | |
| Common Stock Issuance | — | — | — | — | — | — | $0 | $0 | $141.0m | $0 | $0 | |
| Common Stock Payments | — | — | — | — | — | — | $0 | $0 | $0 | ($25.3m) | ($39.9m) | |
| Issuance Of Capital Stock | — | — | — | — | — | — | $0 | $0 | $141.0m | $0 | $0 | |
| Repurchase Of Capital Stock | — | — | — | — | — | — | $0 | $0 | $0 | ($25.3m) | ($39.9m) | |
| Dividends Payable, Current | — | — | — | $2 | — | — | — | — | — | — | — | |
| Net Other Financing Charges | — | — | — | — | — | — | ($7.9m) | ($13.6m) | ($13.8m) | ($6.4m) | ($6.2m) | |
| Net Cash Provided by (Used in) Financing Activities | $69k |
$57.4m
+83033.05%
|
$293k
-99.49%
|
$1.1m
+280.82%
|
$702k
-37.12%
|
($8.1m)
-1260.08%
|
$1.7m
+120.80%
|
($10.9m)
-740.91%
|
$140.7m
+1395.62%
|
($17.0m)
-112.08%
|
($32.9m)
-93.75%
|
|
| Net increase (decrease) in cash and cash equivalents | ($14.3m) | $43.6m | ($40.9m) | $73.0m | $40.7m | $41.2m | $127.0m | ($160.8m) | $379.9m | $191.6m | — | |
| Cash and cash equivalents – beginning of period | — | — | $57.5m | $16.6m | $89.5m | $130.2m | $298.4m | $137.6m | $517.6m | $709.2m | — | |
| Beginning Cash Position | — | — | — | — | — | — | $171.4m | $298.4m | $137.6m | $517.6m | $580.7m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | — | $298.4m | $137.6m | $517.6m | $709.2m | $755.9m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $80k | $368k | $298k | $1.1m | $758k | $4.1m | $9.6m | $2.8m | $13.5m | $14.7m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | $0 | $705k | $1.4m | $466k | — | |
| Additional Financial Items | ||||||||||||
| Equity Securities, FV-NI, Gain (Loss) | — | — | — | — | — | — | — | $3.0m | $5.1m | $972k | — | |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | — | — | — | $3.0m | $5.1m | $972k | — | |
| General and Administrative Expense | $7.9m | $7.3m | $15.9m | — | — | — | — | — | $59.0m | $63.1m | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $1.5m | ($33.1m) | $13.2m | $21.6m | $23.1m | $52.4m | $69.2m | — | |
| Operating Expenses | $19.3m | $18.7m | $35.8m | — | — | — | — | — | $190.4m | $206.5m | — | |
| Accretion of discount | — | — | — | — | — | ($5k) | $17k | $1.3m | ($835k) | ($350k) | — | |
| Reduction in the carrying amount of right-of-use asset | — | — | — | $243k | $793k | $292k | $247k | $262k | $278k | $295k | — | |
| Realized loss on sale of available-for-sale securities | — | — | — | — | — | — | $762k | $0 | $0 | — | — | |
| Acquired in-process research and development | — | — | — | — | — | — | $0 | $81.5m | $0 | $0 | — | |
| Change in fair value of equity securities | — | — | — | — | — | $0 | $0 | ($3.0m) | ($5.1m) | ($972k) | — | |
| Operating lease liability | — | — | — | ($277k) | ($919k) | $864k | ($307k) | ($338k) | ($369k) | ($401k) | — | |
| Proceeds from sale of available-for-sale securities | — | — | — | — | $5.0m | — | $19.2m | $0 | $0 | — | — | |
| Purchase of equity securities | — | — | — | — | — | — | $0 | ($13.5m) | $0 | $0 | — | |
| Proceeds from exercise of stock options | $80k | $368k | $298k | $1.1m | $758k | $4.1m | $9.6m | $2.8m | $13.5m | $14.7m | — | |
| Payment of liabilities arising from asset acquisition | — | — | — | — | — | — | ($738k) | ($12.7m) | ($12.9m) | ($4.6m) | — | |
| Cash paid for income taxes | — | — | — | — | $2.8m | $3.0m | $7.7m | $50.5m | $68.5m | $72.0m | — | |
| Liabilities arising from asset acquisition | — | — | — | — | — | — | $27.7m | $1.9m | $0 | $0 | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | — | $1.7m | ($10.9m) | $140.7m | ($17.0m) | ($32.9m) | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | — | $9.2m | ($293.5m) | ($556k) | ($58k) | ($85k) | |
| Change In Account Payable | — | — | — | — | — | — | $1.2m | $10.8m | $1.8m | ($5.4m) | ($4.0m) | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | — | $127.0m | ($160.8m) | $379.9m | $191.6m | — | |
| Change In Payable | — | — | — | — | — | — | $1.2m | $10.8m | $1.8m | ($5.4m) | ($4.0m) | |
| Change In Prepaid Assets | — | — | — | — | — | — | ($807k) | ($5.8m) | ($8.5m) | ($177k) | ($4.7m) | |
| Changes In Cash | — | — | — | — | — | — | $127.0m | ($160.8m) | $379.9m | $191.6m | $175.2m | |
| End Cash Position | — | — | — | — | — | — | $298.4m | $137.6m | $517.6m | $709.2m | $755.9m | |
| Financing Cash Flow | — | — | — | — | — | — | $1.7m |
($10.9m)
-740.91%
|
$140.7m
+1395.62%
|
($17.0m)
-112.08%
|
($32.9m)
-93.75%
|
|
| Free Cash Flow | — | — | — | — | — | — | $116.0m | $61.9m | $239.3m | $208.6m | $208.1m | |
| Gain Loss On Sale Of PPE | — | — | — | — | — | $292k | $247k | $262k | — | — | $270k | |
| Investing Cash Flow | — | — | — | — | — | — | $9.2m | ($293.5m) | ($556k) | ($58k) | ($85k) | |
| Net Intangibles Purchase And Sale | — | — | — | — | — | — | $0 | ($81.5m) | $0 | $0 | $0 | |
| Net Investment Purchase And Sale | — | — | — | — | — | — | $19.2m | ($13.5m) | $0 | $0 | $19.2m | |
| Net PPE Purchase And Sale | — | — | — | — | — | — | ($29k) | ($231k) | ($556k) | ($58k) | ($85k) | |
| Operating Gains Losses | — | — | — | — | — | $292k | $762k | $262k | — | — | $270k | |
| Other Non Cash Items | — | — | — | — | — | — | $4.4m | $83.2m | ($557k) | ($55k) | — | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | — | $9.6m | $2.8m | $13.5m | $14.7m | $13.2m | |
| Purchase Of Intangibles | — | — | — | — | — | — | $0 | ($81.5m) | $0 | $0 | $0 | |
| Purchase Of Investment | — | — | — | — | — | — | $0 | ($13.5m) | $0 | $0 | $0 | |
| Purchase Of PPE | $96k | $96k | $92k | $19k | $11k | $1.0m | ($29k) | ($231k) | ($556k) | ($58k) | ($373k) | |
| Sale Of Investment | — | — | — | — | — | $0 | $19.2m | $0 | $0 | — | $19.2m | |
| Unrealized Gain Loss On Investment Securities | — | — | — | — | — | — | $0 | ($3.0m) | ($5.1m) | ($972k) | ($3.1m) |